May 10, 2023 / Press Releases

NARAL Pro-Choice America Celebrates FDA Advisory Committee’s Historic Recommendation to Allow Birth Control Option Be Available Over The Counter

For Immediate Release: Wednesday, May 10, 2023

Contact: [email protected]

Washington, DC — Today, the Food and Drug Administration (FDA) Advisory Committee voted unanimously to recommend OPILL—a birth control pill option—be made available over the counter. While the FDA will now need to make a final decision, this historic recommendation could lead to the first over-the-counter birth control option.

NARAL Pro-Choice America President Mini Timmaraju released the following statement in response:

“As reproductive freedom in our country faces an unprecedented crisis, expanding access to proven, safe, and effective contraception has never been more important. This recommendation from the FDA Advisory Committee is not only historic—it is simply the right thing to do. Thank you to the tireless advocates, including the Free the Pill Coalition, who have spent decades working to ensure birth control can become more accessible—giving more people more freedom to decide whether or when to start or grow a family.”


For over 50 years, NARAL Pro-Choice America has fought to protect and advance reproductive freedom at the federal and state levels—including access to abortion care, birth control, pregnancy and post-partum care, and paid family leave—for everybody. NARAL is powered by its 4 million members from every state and congressional district in the country, representing the 8 in 10 Americans who support legal abortion.







Everyone should be able to decide if, when, how, and with whom they start or grow a family.

Sign up for Updates
By taking this action you are affirming your membership in NARAL Pro-Choice America. What's this?
By providing your phone number, you are consenting to receive mobile alerts from NARAL Pro Choice America at 59791. Message and data rates apply. Frequency varies. Text STOP to end. Text HELP for help. Privacy Policy and Terms & Conditions.